Competing Offer Not Likely, Given Price
Merck Picks Best Horse' In $1.1B Sirna Buyout: Analyst
Merck & Co. Inc.'s plan to buy Sirna Therapeutics Inc. for $1.1 billion, despite two of Sirna's major programs tied to partnerships with other pharma firms, casts a shadow over the Merck deal with Alnylam Pharmaceuticals Inc., rival of Sirna in the RNA interference space. (BioWorld Today)